CAST PHARMA, a premier European 3D pharmaceutical and biomedical animation production company, is pleased to announce the availability of an advanced Demo-DVD to make its audiovisual material more widely available to the existing and further customers from the biomedical and pharmaceutical domains.

Results from the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey of more than 500 rheumatoid arthritis (RA) patients throughout Europe and Canada revealed a majority of patients still suffer from pain (79 percent), fatigue (67 percent) and joint stiffness (57 percent) on a regular basis despite current treatment, while more than half (51 percent) of RA patients feel their disease controls their life.

First DataBank Europe (FDBE) is pleased to announce, in association with The Guild of Healthcare Pharmacists (GHP) and the UK Clinical Pharmacy Association (UKCPA), the 2010 FDBE/GHP/UKCPA Information Technology Award.

Can an aspirin a day keep the doctor away? New research, part of the EU-funded BIOMED (Biomedicine and health) programme, shows it can't all the time. The researchers have discovered that although regular use of aspirin can reduce the rate of non-fatal heart attacks or stroke by around 12%, there is a 33% increase in the risk of internal bleeding in people with no history of relevant disease (primary prevention). The findings are published in The Lancet journal.

"Pioneers" was the headline when Science magazine covered the launch of the academic networking platform ResearchGATE exactly one year ago. In a very short time, a small group of pioneers in scientific communication, located at Harvard University and Hannover Medical School (Germany), has managed to create a worldwide community with more than 50,000 members from 196 countries.

The new H1N1 virus is only distantly related to its nearest relatives, suggesting that its genes may have been circulating undetected in pig populations for some time, according to new research published online by the journal Science.

The fight against leukaemia and malaria - two of the world's most virulent diseases - was rewarded in two out of the four categories at the recent European Inventor of the Year awards. Swiss medicinal chemist Dr Jürg Zimmermann along with US oncologist Dr Brian Druker won the award in the Industry category for his invention of the drug Glivec. Glivec has a 98% remission rate in people suffering from chronic myelogenous leukaemia (CML) - a rare form of leukaemia that affects about 10,000 people every year.